Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2011 Oct 15;184(8):972-9.
doi: 10.1164/rccm.201105-0827WS.

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

Payam Nahid  1 , Jussi Saukkonen, William R Mac Kenzie, John L Johnson, Patrick P J Phillips, Janet Andersen, Erin Bliven-Sizemore, John T Belisle, W Henry Boom, Annie Luetkemeyer, Thomas B Campbell, Kathleen D Eisenach, Richard Hafner, Jeffrey L Lennox, Mamodikoe Makhene, Susan Swindells, M Elsa Villarino, Marc Weiner, Constance Benson, William Burman; National Institutes of Health; Centers for Disease Control and Prevention
Affiliations
Guideline

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

Payam Nahid et al. Am J Respir Crit Care Med. .

Abstract

The Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. The goals were to assess recent surrogate marker research and to provide specific recommendations for (1) the qualification and validation of biomarkers of treatment outcome; (2) the standardization of specimen and data collection for future clinical trials, including a minimum set of samples and collection time points; and (3) the creation ofa specimen repository to support biomarker testing. This article summarizes these recommendations and provides a roadmap for their implementation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Sources for potential host and pathogen biomarkers of treatment response.
See this image and copyright information in PMC

References

    1. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100–2109 - PubMed
    1. Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 2006;367:945–947 - PubMed
    1. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348–1354 - PubMed
    1. Nuermberger E. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 2008;29:542–551 - PubMed
    1. Davies GR, Phillips PP, Nunn AJ. Biomarkers and surrogate end points in clinical trials of tuberculosis treatment. J Infect Dis 2007;196:648–649, author reply 649–650 - PubMed

Publication types